Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)
Close on Nov 17, 2026Market cap $6.07BP/E –Yield –
Arrowhead Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Arrowhead Pharmaceuticals's total assets was $2.11B at Jun 30, 2026. For fiscal 2025 it was $1.39B, up 21.5% from the year before. Over ten years it grew 26.5% a year on average. The highest annual figure on record is $1.39B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.39B | +21.5% |
| FY2024 | Sep 30, 2024 | $1.14B | +48.9% |
| FY2023 | Sep 30, 2023 | $765.55M | +10.6% |
| FY2022 | Sep 30, 2022 | $691.94M | -2.6% |
| FY2021 | Sep 30, 2021 | $710.15M | +35.9% |
| FY2020 | Sep 30, 2020 | $522.50M | +49.4% |
| FY2019 | Sep 30, 2019 | $349.85M | +213.5% |
| FY2018 | Sep 30, 2018 | $111.61M | +7.3% |
| FY2017 | Sep 30, 2017 | $104.02M | -18.8% |
| FY2016 | Sep 30, 2016 | $128.18M | -3.1% |
| FY2015 | Sep 30, 2015 | $132.27M | -27.7% |
| FY2014 | Sep 30, 2014 | $182.82M | +389.7% |
| FY2013 | Sep 30, 2013 | $37.33M | +125.9% |
| FY2012 | Sep 30, 2012 | $16.53M | +4.0% |
| FY2011 | Sep 30, 2011 | $15.89M | +28.6% |
| FY2010 | Sep 30, 2010 | $12.35M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $2.11B | +53.0% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $2.27B | +44.2% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $1.60B | +58.3% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $1.39B | +21.5% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $1.38B | +56.2% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $1.57B | +64.7% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $1.01B | +61.9% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $1.14B | +48.9% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $883.76M | +11.0% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $955.15M | +7.2% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $626.29M | -29.7% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $765.55M | +10.6% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $795.86M | +5.9% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $891.31M | +26.7% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $891.49M | +39.6% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $691.94M | -2.6% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $751.78M | +2.3% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $703.58M | -7.0% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $638.54M | +27.9% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $710.15M | +35.9% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $734.93M | +32.2% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $756.80M | +34.9% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $499.25M | -15.0% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $522.50M | +49.4% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $555.73M | +65.0% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $561.08M | +68.0% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $587.60M | +72.3% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $349.85M | +213.5% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $336.83M | +198.3% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $333.94M | +162.9% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $340.95M | +286.5% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $111.61M | +7.3% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $112.90M | -1.9% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $127.00M | +0.1% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $88.22M | -38.8% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $104.02M | -18.8% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $115.08M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $126.87M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $144.26M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $128.18M | – |
See a number that looks wrong?